bims-fagtap Biomed News
on Phage therapies and applications
Issue of 2026–02–15
37 papers selected by
Luca Bolliger, lxBio



  1. Expert Rev Anti Infect Ther. 2026 Feb 13.
       INTRODUCTION: Antimicrobial resistance is undermining the effectiveness of conventional antibiotics and represents a critical global health challenge. This review evaluates the resurgence of bacteriophage therapy as a precision strategy to address multidrug-resistant bacterial infections.
    AREAS COVERED: The review critically examines the biological principles of phage therapy, including host specificity, lytic activity, and biofilm disruption, and synthesizes current evidence from clinical, veterinary, and environmental applications. Recent technological advances such as engineered phages, phage cocktails, and novel delivery systems are discussed together with regulatory, manufacturing, and translational barriers. A structured analysis of contemporary literature, encompassing experimental studies and early clinical investigations, was undertaken to assess therapeutic potential and limitations.
    EXPERT OPINION: Although phage therapy offers a promising complement to existing antimicrobials, routine clinical implementation requires harmonized regulatory pathways, scalable production standards, and rigorously designed clinical trials. Strategic international collaboration and integration of emerging technologies will be pivotal in advancing phage therapy toward sustainable clinical adoption.
    Keywords:  Antimicrobial resistance; lytic-lysogenic; phage cocktails; phages; superbugs
    DOI:  https://doi.org/10.1080/14787210.2026.2632669
  2. Sci Rep. 2026 Feb 12. 16(1): 6337
      Antibiotic-resistant methicillin-resistant Staphylococcus aureus (MRSA) poses a significant challenge in managing wound infections. Bacteriophage therapy has emerged as a promising alternative or adjunct to traditional antibiotics. This study evaluated the therapeutic potential of a temperate, uncharacterized phage preparation induced from the S. aureus reference strain ATCC 25,923 using mitomycin C (MitC) for topical treatment of superficial MRSA-infected wounds in a rabbit model, both alone and combined with vancomycin. Key wound healing markers (collagen 1, MMP1, PDGF, FGF2) and inflammatory cytokines (IL-1, IL-6, TNF-α) were assessed alongside immunohistochemical analysis of IL-6 and TNF-α expression. The induced lysogenic phage demonstrated lytic activity against MRSA, resulting in a wound healing rate of 87.89%, which increased to 93.63% with combined vancomycin treatment. Enhanced healing correlated with elevated collagen, PDGF, and FGF2 expression and significant downregulation of pro-inflammatory cytokines (p < 0.0001). Immunohistochemistry confirmed decreased IL-6 and TNF-α expression in wound inflammatory cells. These findings provide preliminary in vivo evidence supporting phage-antibiotic synergy for treating MRSA wounds. Although promising, the phage preparation remains uncharacterized, limiting reproducibility and translational readiness. Further research is needed to characterize active phage components, evaluate safety, and optimize therapeutic protocols before clinical application. This study pioneers the in vivo use of temperate phages combined with antibiotics for MRSA wound treatment, addressing antibiotic resistance issues by improving wound closure, promoting healing factor expression, and reducing inflammation. These results lay an important foundation for developing novel therapies against resistant bacterial infections.
    Keywords:  Antibacterial activity; In vivo rabbit model; MRSA; Prophages; Wound healing; Wound infection
    DOI:  https://doi.org/10.1038/s41598-025-34474-6
  3. Biotechnol Adv. 2026 Feb 05. pii: S0734-9750(26)00045-5. [Epub ahead of print]88 108839
      Bacterial infections continue to persist as a major global healthcare challenge, exacerbated by the alarming rise of antimicrobial resistance (AMR) that renders conventional antibiotics increasingly ineffective. In response, bacteriophage therapy has re-emerged as a viable alternative to antibiotics, leveraging the natural ability of phages to target and lyse specific bacterial pathogens. However, phage therapy is subjected to diverse challenges such as phage stability, targeted delivery, and bacterial resistance limiting its clinical applications. Recent mechanistic advancements in nanotechnology present a groundbreaking solution by enabling precise nano-based engineering of phages with enhanced therapeutic properties. This review examines the integration of nanotechnology tools and products with phage therapy, highlighting innovative strategies such as nanomaterial-based encapsulation, functionalization, improve stability, precise delivery and inhibit toxicological exposure. Furthermore, nanotechnology facilitates controlled release, prolonged circulation, and synergistic combinations with dynamic phage therapies. The review also investigates perspectives related to the challenges such as standardization, scalability, immunogenicity, and regulatory barriers of phage therapy, encompassing the future emphasis on the development of biocompatible carriers. By overcoming these obstacles, nanotechnology-enabled phage therapy has the potential to improve the treatment of multidrug-resistant bacteria, offering a more targeted, adaptable, and sustainable approach to combating the growing threat of AMR.
    Keywords:  Antimicrobials; Bacteriophage; Biofilm; Nanotechnology; Targeted delivery
    DOI:  https://doi.org/10.1016/j.biotechadv.2026.108839
  4. J Infect Dis. 2026 Feb 13. pii: jiag096. [Epub ahead of print]
      This review explores mammalian immune responses to phages with a particular emphasis on human immune responses to therapeutic phages and their potential implications for the outcomes of phage therapy. Despite the ubiquity of phages in the human microbiome, particularly in the gut (the phageome), research on immunological mechanisms governing immune responses to both endogenous and therapeutic phages are still in their infancy. We highlight key components of the immune system that contribute to clearance of phages in vivo and examine how various factors- including patient-specific variables, treatment regimens and phage characteristics can influence immune responses and, consequently, phage pharmacokinetics during therapy. A clearer understanding of human immune responses to phages is urgently needed to inform the development of more targeted and effective personalised phage therapies - an essential step in combating the escalating threat of antimicrobial resistance.
    Keywords:  Anti-phage antibodies; Immune response; Phage immunogenicity; Phage pharmacokinetics; Phage therapy; Therapeutic phage monitoring
    DOI:  https://doi.org/10.1093/infdis/jiag096
  5. Cell Host Microbe. 2026 Feb 11. pii: S1931-3128(26)00040-5. [Epub ahead of print]34(2): 187-189
      Bacteriophage therapy has regained popularity in treating antibiotic-resistant bacterial infections. However, bacteria encode clever ways to evade lytic cell death inflicted by phages. In this issue, Zang and coworkers report a small molecule that inhibits type II Thoeris anti-phage systems from pathogens and re-sensitizes bacteria to phage-induced cell lysis.
    DOI:  https://doi.org/10.1016/j.chom.2026.01.015
  6. Nat Commun. 2026 Feb 07.
      Phage therapy is emerging as a promising alternative to antibiotics for treating various infections. However, there have been no prior studies on using bacteriophages for peritonitis in patients undergoing peritoneal dialysis. This report presents the successful treatment of refractory peritonitis in a 71-year-old male peritoneal dialysis patient using bacteriophages combined with antibiotics. The patient has a history of refractory and repeat peritonitis caused by Staphylococcus haemolyticus, which was resolved through simultaneous catheter replacement (SCR). Subsequently, the patient experiences another episode of refractory peritonitis due to Klebsiella pneumoniae. Although this strain is found to be susceptible to amikacin and imipenem, a 14-day course of treatment with these antibiotics in the abdominal cavity fails to resolve the peritonitis. Combined with antibiotic therapy, the patient is successfully treated with intraperitoneal phage therapy targeting his bacterial isolate. We monitor the longitudinal progression of phage loads, phage-neutralizing antibodies, interleukin-6 levels, and lipopolysaccharide concentrations in the dialysate effluent during the bacteriophage therapy. The combination of a phage cocktail and imipenem (IPM) demonstrates a greater effect in killing bacteria than either treatment alone, which indicates that a synergistic effect exists between the phage cocktail and IPM. Intraperitoneal IPM is discontinued after a 3-week course of treatment. At the same time, oral fluconazole is given to prevent fungal infections. The patient is discharged without any antibiotics. After this round of treatment, the patient remains healthy during the one-month follow-up. Our study suggests that personalized phage therapy combined with sensitive antibiotics can play a significant role in managing refractory peritonitis in patients undergoing peritoneal dialysis, showing promise for future applications.
    DOI:  https://doi.org/10.1038/s41467-026-69154-0
  7. Microbiol Res. 2026 Feb 07. pii: S0944-5013(26)00037-6. [Epub ahead of print]307 128473
      The withdrawal of antibiotic growth promoters from poultry production has led to the resurgence of Clostridium perfringens-induced necrotic enteritis (NE), resulting in annual global economic losses exceeding $6 billion. With conventional antibiotics becoming less accessible for disease prevention, there is an urgent need for effective non-antibiotic alternatives. Bacteriophage therapy represents a promising approach, although its utility is often constrained by narrow host range and rapid emergence of phage resistance. Here, we present a cross-resistance-guided strategy for rational phage cocktail design that combines phages with complementary and non-overlapping resistance profiles. Through systematic screening of eight C. perfringens-specific phages, we identified two host-range groups exhibiting complementary host ranges and reciprocal cross-resistance. A cocktail comprising CPD4 (siphovirus-like, 52,658 bp) and CPD7 (podovirus-like, 18,958 bp) was formulated based on their potency and divergence. Genomic and morphological analyses confirmed their strictly lytic lifecycle, absence of lysogenic or virulence genes, and high physicochemical stability. Notably, the cocktail demonstrated reciprocal cross-resistance, where resistance to one phage did not confer resistance to the other, thereby ensuring sustained lytic activity and mitigating the emergence of resistant strains. Furthermore, in vivo evaluation demonstrated that the cocktail significantly improved survival, reduced intestinal lesions, and suppressed C. perfringens colonization in NE-challenged chickens. Together, these results establish this cross-resistance-guided phage cocktail design as a practical and cost-effective strategy for NE mitigation in poultry.
    Keywords:  Bacteriophage; Clostridium perfringens; Cross-resistance; Necrotic enteritis; Phage cocktail
    DOI:  https://doi.org/10.1016/j.micres.2026.128473
  8. Phage (New Rochelle). 2025 Dec;6(4): 272-281
      Bacteriophages, viruses that specifically infect bacteria, emerge as precision tools to combat multidrug-resistant infections and modulate host immunity. This review explores the dynamic interactions between bacteriophages and both bacterial and eukaryotic hosts, emphasizing their therapeutic potential and biotechnological applications. We discuss mechanisms of phage entry into mammalian tissues, including traversal of the blood-brain barrier, and their roles in shaping innate and adaptive immune responses. The review also highlights advances in phage engineering, such as non-lytic phagemid systems, clustered regularly interspersed short palindromic repeats (CRISPR)-based antimicrobials, and quorum-sensing disruption strategies. These innovations position bacteriophages as versatile agents in modern microbiology, with implications for personalized medicine, immunotherapy, and synthetic biology.
    Keywords:  CRISPR antimicrobials; bacteriophage therapy; blood–brain barrier; immune modulation; phage engineering
    DOI:  https://doi.org/10.1177/26416549251384321
  9. Curr Urol. 2026 Mar;20(2): 82-88
       Background: Urinary tract infections (UTIs) caused by uropathogenic E. coli (UPEC) pose a global health challenge, largely due to UPEC biofilms that drive persistent infections and antibiotic resistance.
    Materials and methods: To explore the role of UPEC biofilms in antibiotic-resistant UTIs and summarize emerging therapeutic strategies, this study conducted a systematic review adhering to PRISMA guidelines and registered in PROSPERO (CRD420251040212). A structured search of PubMed, Google Scholar, Scopus, and Web of Science identified English-language studies published up to 2024, with 57 eligible studies selected after three-stage screening and analyzed via thematic synthesis.
    Results: This study explored UPEC biofilms enhance resistance through extracellular matrix barriers, persister cell formation, efflux pump upregulation, and horizontal gene transfer; emerging therapies including bacteriophage therapy, quorum-sensing inhibitors, and nanoparticle-based drug delivery effectively target biofilms by penetration, signaling disruption, and improved drug efficacy. Additional approaches such as antibiofilm peptides, probiotics, and immunotherapy also demonstrate potential.
    Conclusions: The UPEC biofilms are key to chronic UTIs, and novel targeted therapies offer promising solutions, but clinical validation, regulatory hurdles, and combination therapy optimization are critical for translation to clinical practice.
    Keywords:  Antibiotic resistance; Bacteriophage therapy; Biofilms; Quorum-sensing inhibitors; Nanoparticle; Uropathogenic E. coli
    DOI:  https://doi.org/10.1097/CU9.0000000000000308
  10. Nat Commun. 2026 Feb 11.
      Bacteriophage-antibiotic coadministration is increasingly used for refractory infections, yet the in vivo interactions among phages, bacteria, antibiotics, and host immunity remain poorly defined. We report a longitudinal, multiomic case analysis of a male in his seventies with cystic fibrosis (CF) experiencing an acute-on-chronic pulmonary exacerbation caused by multidrug-resistant (MDR) Pseudomonas aeruginosa. After colistin discontinuation due to nephrotoxicity, ciprofloxacin was initiated, with an intravenous two-phage cocktail introduced days later. Distinct mucoid and nonmucoid bacterial subpopulations associated differentially with antibiotic versus phage exposure, consistent with nonoverlapping selective pressures. Phage activity was temporally constrained, with one phage dominating early bacterial and genomic signals before attenuating after approximately seven days, despite continued genomic detectability. In contrast, the second phage showed no evidence of productive activity. This asymmetry coincided with phage-reactive humoral immunity: pre-existing IgM was associated with lack of recoverability of one phage, while treatment-associated IgM emergence temporally tracked attenuation of the dominant phage. Although phage-resistant variants arose during therapy, they showed limited expansion relative to susceptible populations. These findings define a mechanistic framework-chemobiotherapy-in which chemical and biological antimicrobials coordinate through ecological and immunologic complementarity rather than direct pharmacologic synergy.
    DOI:  https://doi.org/10.1038/s41467-026-69247-w
  11. Appl Environ Microbiol. 2026 Feb 13. e0242325
      Given the high pathogenicity and escalating antimicrobial resistance of Klebsiella pneumoniae, the efficacy of conventional antibiotics is waning, creating an urgent need for alternative therapeutic strategies. Phage therapy has emerged as a particularly promising approach for combating highly virulent and multidrug-resistant K. pneumoniae due to its target specificity and potent bactericidal activity. This study isolated a lytic K. pneumoniae phage vB_kpnP_ZB27 (ZB27) from domestic sewage in Hefei, China. This phage demonstrated specificity against clinically relevant serotypes K1 and K2. It exhibited remarkable stability across a wide range of temperatures (20°C-50°C) and pH values (4-11). Crucially, genomic analysis confirmed the absence of antibiotic resistance or virulence genes. These findings collectively indicated that phage ZB27 is a promising and safe candidate for phage therapy. The core objective of this study was to optimize the phage fermentation process. To enhance phage yield, we optimized inoculum concentration and medium composition. Laboratory-scale fermentation determined the optimal multiplicity of infection to be 0.0001. Furthermore, response surface methodology optimized key additive concentrations: sorbitol to 46.8 mg/mL, soybean meal to 59.9 mg/mL, and calcium chloride to 1 mM. This optimized protocol increased phage yield by 2.96-fold during scale-up, establishing an effective method for industrial production of therapeutic phages.IMPORTANCETraditional phage preparations typically consist of a single phage with a narrow host range, often requiring the use of complex phage cocktails to cover target strains, which substantially increases production costs. In this study, we successfully isolated broad-spectrum phages capable of lysing both K1 and K2 serotypes, thereby significantly expanding the bactericidal spectrum of the phage preparation. Furthermore, through industrial process optimization, we achieved dual benefits: reducing host bacterial consumption while increasing phage yield. These findings demonstrate that artificially optimized production processes can improve both the economic feasibility and safety of phage biomanufacturing, thus opening new pathways for the industrialization of phage therapy.
    Keywords:  Klebsiella pneumoniae phage; RSM; expanded production; production optimization
    DOI:  https://doi.org/10.1128/aem.02423-25
  12. ACS Nano. 2026 Feb 09.
      Biofilms formed by bacterial symbiosis significantly strengthen bacterial resistance to external interference and cause chronic infections. Herein, a chemodynamic therapy (CDT) and photodynamic therapy (PDT) coarmed bacteriophage cocktail was developed to eradicate Staphylococcus aureus biofilms by conjugating aggregation-induced emission photosensitizer (AIE PSs), glucose oxidase (GOx), and horseradish peroxidase (HRP) on the bacteriophage surface. Leveraging the particular specificity of the bacteriophage toward host bacteria, the three conjugates can penetrate the biofilm and colocalize on the inner bacterial surface. When thus enriched, AIE PSs exhibited intensified fluorescence, enabling labeling and killing pathogens via photoirradiation-generated singlet oxygen. After combining AIE PSs with GOx/HRP, which can convert glucose nutrients into H2O2 and ultimately to hydroxyl radicals via cascade catalysis, the bactericidal efficiency was dramatically improved compared to individual phage-CDT (>468%) or phage-PDT (>290%) at the same PFU concentration of phage. The colocalized PSs and enzymes on the confined space of the bacterial surface are mutually promoted in the microenvironment of the biofilm, realizing synergistic enhancement. This strengthened bacteriophage cocktail offers an effective strategy for treating biofilm-related clinical superbug infections.
    Keywords:  bacteriophage cocktail; biofilm; photosensitizer; synergistic therapy; targeting
    DOI:  https://doi.org/10.1021/acsnano.5c19780
  13. Health Sci Rep. 2026 Feb;9(2): e71798
       Background and Aims: Chronic wounds, including diabetic foot, venous, and pressure ulcers, remain a major unmet medical challenge due to their prevalence, severity, and the limited efficacy of current treatments. These wounds are inherently multifactorial, requiring simultaneous intervention across all chronicity-inducing factors. Neither medical devices nor single pharmacological agents are sufficient, as they cannot comprehensively address the multiple therapeutic needs. This review aims to propose an integrative therapeutic approach capable of targeting all relevant mechanisms.
    Methods: A narrative review of the literature was conducted, analyzing over 100 peer-reviewed articles on chronic wound pathophysiology and therapeutic strategies. Sources were identified through searches in PubMed, Scopus, and Web of Science, complemented by manual reference screening. Studies discussing the mechanisms of wound chronicity, as well as drugs and biologics with potential therapeutic activity, were included.
    Results: The analysis revealed that current therapeutic options, including devices, drugs, and biologics, address only isolated aspects of chronic wound pathophysiology. No single agent or device is capable of comprehensively targeting all relevant mechanisms. However, evidence suggests that combining already-approved drugs and/or biologics may provide a synergistic effect, simultaneously targeting inflammation, infection, impaired angiogenesis, oxidative stress, and defective tissue remodeling. Importantly, the use of approved components leverages established pharmacological and safety profiles, potentially streamlining development and regulatory approval.
    Conclusion: A topical combination product integrating multiple agents offers a promising strategy to overcome the limitations of current treatments. Advances in the understanding of wound pathophysiology and the availability of diverse active molecules create new opportunities to design effective and holistic therapies. Such combination products could transform the management of chronic wounds and represent the next generation of treatment approaches.
    Keywords:  chronic wounds; combination products; diabetic foot ulcers; pressure ulcers; venous ulcers; wound healing
    DOI:  https://doi.org/10.1002/hsr2.71798
  14. Diagnostics (Basel). 2026 Jan 23. pii: 373. [Epub ahead of print]16(3):
      Over recent years, venous ulcer wound care has experienced significant advancements through the application of machine learning (ML) models. The aim of the present study is a systematic, comprehensive analysis of prior research studies in this field covering the period between 2001 and August 2025. By searching multiple academic databases, including the Web of Science, Scopus, and PubMed, using relevant keywords and different queries, and screening reference lists of previously published manuscripts and review papers with a focus on the application of artificial intelligence in dermatology and medicine, an initial set of potential studies for review was obtained. To ensure the scope and relevance of the review, several inclusion and exclusion criteria were used to derive the final set of relevant research studies upon which a database for research data management was created. As a result, a total of 79 relevant research studies were comprehensively analysed, upon which detailed meta-analysis and analysis of application areas of ML models within venous ulcer wound care were conducted. Afterwards, a summary of benefits for medical systems and patients was given along with a general discussion regarding ML model limitations, trends, and opportunities, as well as research studies' limitations and possible future research directions. The presented analyses may be valuable for researchers interested in applying ML models not only to venous ulcer wound care but also to other types of chronic wound care.
    Keywords:  chronic wounds; machine learning; venous ulcers; wound care
    DOI:  https://doi.org/10.3390/diagnostics16030373
  15. Int J Antimicrob Agents. 2026 Feb 05. pii: S0924-8579(26)00020-8. [Epub ahead of print] 107731
      
    DOI:  https://doi.org/10.1016/j.ijantimicag.2026.107731
  16. Bull Exp Biol Med. 2026 Feb 10.
      The global spread of multidrug-resistant pathogens underscores the urgent need for novel therapeutic strategies against bacterial infections. One promising approach is phage therapy, which utilizes lytic bacteriophages that exhibit high specificity for their bacterial hosts. In this study, we isolated a novel bacteriophage, vB_EcoA_PHZVL, belonging to the family Autographiviridae, which demonstrates potent lytic activity against a clinical strain of adherent-invasive Escherichia coli (AIEC) isolated from a patient with Crohn's disease (CD). We further demonstrated that both plaque morphology and phage adsorption efficiency are influenced by the composition of the culture medium and the carbon source, likely due to alterations in LPS structure on the bacterial surface. These findings enhance our understanding of phage-host interactions and highlight the potential of vB_EcoA_PHZVL as a candidate for phage-based therapy in CD.
    Keywords:  Crohn’s disease; adhesive-invasive Escherichia coli (AIEC); bacteriophages; depolymerases; phage therapy
    DOI:  https://doi.org/10.1007/s10517-026-06582-4
  17. Microb Biotechnol. 2026 Feb;19(2): e70315
      Ralstonia solanacearum (RS) is a soil-borne phytopathogen responsible for bacterial wilt disease on a wide range of crops worldwide. Bacteriophage biocontrol is a promising sustainable RS management method. However, more work is needed to design methods to store, ship and apply phage that are effective, scalable and environmentally friendly. Here, we investigate the use of wood hemicellulose excipients-glucuronoxylans (GX) and galactoglucomannans (GGM) - to encapsulate phage PYO4, which can infect the pandemic RS strain UW551. Yield and preservation efficiencies of GX and GGM were compared to the conventional excipient maltodextrin (MD). Encapsulation via spray drying was carried out at two inlet/outlet temperatures, and the resulting powders were stored at room temperature or at 4°C. Phage titers were measured after spray drying, and then weekly for 25 weeks. GX yielded the highest titre of encapsulated phage and preserved phage survival effectively at 4°C. Phages encapsulated with MD had the highest stability at room temperature. GGM had poor results, with low survival after spray drying and low long-term stability at either temperature. In vitro experiments demonstrated that encapsulated phages inhibited RS as efficiently as unencapsulated phage. Phage encapsulated in GX and MD also reduced bacterial wilt symptoms on tomato. At low MOIs, phage encapsulated in GX and MD reduced symptoms more than unencapsulated phage, suggesting the excipients themselves could be affecting RS. We found that GX alone could inhibit RS growth in vitro and reduce disease progression in planta without phage. MD alone couldn't significantly reduce bacterial wilt symptoms or inhibit RS growth in vitro. Together, these results show that the encapsulation of phages in hemicelluloses has great promise for efficient biocontrol methods to combat plant pathogens. Not only are hemicelluloses effective in phage preservation, but also have potential to enhance the biocontrol efficacy of phages through their antimicrobial activities.
    Keywords:   Ralstonia solanacearum ; bacterial wilt disease; bacteriophage survival; phage encapsulation; spray‐dried microencapsulation; wood hemicellulose
    DOI:  https://doi.org/10.1111/1751-7915.70315
  18. PLoS One. 2026 ;21(2): e0340258
      Chronic wounds impose a substantial burden on patients and healthcare systems, necessitating accurate qualification of precise wound analysis for effective diagnosis and treatment. Wound size and the proportional composition of internal tissues are critical indicators of healing progression. Traditional segmentation approaches such as Separate Task Learning (STL) suffer from parameter inefficiency, while Multi-Task Learning (MTL), though efficient, often experiences task imbalance that leads to performance degradation in specific tasks. To overcome these challenges, this study proposes WING-MTL (Wound and Wound Tissue Integrated with Gradient Normalization Multi-Task Learning), a novel MTL framework that dynamically balances gradient magnitudes across tasks to enhance accuracy and training stability. Implemented on an Attention-UNet backbone,and incorporates Gradient Normalization to adjust learning gradients in real time, ensuring balanced optimization for wound and wound tissue segmentation tasks. Quantitative evaluations demonstrate that WING-MTL yields statistically significant improvements over STL and outperforms conventional and advanced MTL methods. Analysis of validation loss revealed convergence of both tasks at the same epoch, indicating balanced learning. Furthermore, improved segmentation performance was observed compared to both STL and MTL approaches, particularly for challenging wound tissue types such as slough and epithelium in qualitative analysis. These findings confirm that WING-MTL addresses the task imbalance inherent in MTL frameworks while maintaining parameter efficiency. WING-MTL was evaluated across diverse backbones, including not only UNet-based model but also Resnet and Transformer-based architectures to validate the architectural flexibility of the proposed framework. Consistent performance improvement across these varied architectures in wound tissue segmentation demonstrates the broad applicability. Furthermore, longitudinal analysis of chronic wound patients was conducted to assess the clinical utility of WING-MTL in real-world scenarios. The framework presents a promising and accurate approach for tracking wound healing progression and serves as a potential adjunct for clinical decision-making in chronic wound care.
    DOI:  https://doi.org/10.1371/journal.pone.0340258
  19. Scand J Caring Sci. 2026 Mar;40(1): e70203
       AIMS AND OBJECTIVES: Negative pressure wound therapy with instillation is increasingly used to treat various wounds. However, there is limited information about its impact on patient experiences. This study aims to explore the experiences of hospitalised patients undergoing negative pressure wound therapy with instillation for different types of wounds and to explore their expectations regarding continuing treatment at home.
    METHODOLOGICAL DESIGN AND JUSTIFICATION: We conducted a qualitative study using semi-structured interviews. 12 patients treated with negative pressure wound therapy with instillation across various hospitals in the Netherlands were interviewed between January 2024 and June 2024. Data were analysed using Braun and Clarke's reflexive thematic analysis.
    ETHICAL ISSUES AND APPROVAL: This study was deemed not subject to the Medical Research Involving Human Subjects Act (WMO), as confirmed by a non-WMO declaration from the ethics committee. All participants provided informed consent prior to the interview.
    RESULTS: Seven themes were generated from the data: feeling prepared for negative pressure wound therapy with instillation, gaining trust and hope because of wound healing, having trust in the expertise of nurses, facing fear and dread during negative pressure wound therapy with instillation, dealing with sleep disturbance, having difficulties with daily living activities, and worrying about undergoing negative pressure wound therapy with instillation at home. Although patients initially faced uncertainties, improved wound healing builds trust in the treatment.
    CONCLUSION: Negative pressure wound therapy with instillation significantly impacts patients' physical and emotional well-being. Patients felt more prepared and confident when provided with detailed explanations about the device and what to expect during treatment. Nurses' unfamiliarity with the treatment further diminished patient trust. For optimal patient care, patients require adequate preparation and support from well-trained nurses to manage the physical and emotional impact of negative pressure wound therapy with instillation, in both hospital and home settings.
    REPORTING METHOD: Adheres to the Reflexive Thematic Analysis Reporting Guidelines.
    PATIENT OR PUBLIC CONTRIBUTION: Patients were involved in the study through interviews.
    Keywords:  negative pressure wound therapy with instillation; patient experiences; qualitative study; semi‐structured interview; treatment impact; wound healing
    DOI:  https://doi.org/10.1111/scs.70203
  20. Environ Microbiol. 2026 Feb;28(2): e70250
      Salmonella enterica is a major global foodborne pathogen whose success across environmental, agricultural and host-associated niches is closely linked to its ability to form biofilms. Importantly, biofilm formation capacity varies substantially among S. enterica serovars, with broad-host-range serovars such as Salmonella typhimurium and Salmonella enteritidis typically exhibiting robust curli- and cellulose-based biofilms, while host-restricted serovars and recently evolved invasive lineages may display reduced or altered biofilm phenotypes. In this review, we synthesise current knowledge on the molecular regulation, ecological significance and public health impact of biofilm formation in S. enterica, with particular emphasis on conserved CsgD-mediated regulatory pathways characterised in strong biofilm-forming serovars. We describe how biofilm development is controlled by interconnected networks involving CsgD, cyclic-di-GMP signalling and environmental sensing systems. Biofilm growth enhances tolerance to environmental stress, disinfectants, antimicrobials and host immune defenses, facilitating long-term persistence on food-processing surfaces, in agricultural environments and within host niches such as the gallbladder. We further discuss emerging antibiofilm strategies, including matrix-degrading enzymes, quorum-sensing inhibitors, bacteriophages and nanotechnology-based approaches. By integrating molecular mechanisms with ecological and serovar-specific perspectives, this review highlights biofilms as a central adaptive strategy of S. enterica and a critical challenge for food safety and public health.
    Keywords:   Salmonella ; biofilm formation; ecological adaptation
    DOI:  https://doi.org/10.1111/1462-2920.70250
  21. J Pharm Pharmacol. 2026 Feb 06. pii: rgag001. [Epub ahead of print]78(2):
       OBJECTIVES: This review summarizes how advances in bioinformatics are transforming pharmacogenomics by enabling prediction of individual drug responses and integration of pharmacogenomic data into clinical practice across multiple therapeutic areas. It aims to highlight key databases, computational tools, and artificial intelligence (AI) approaches that support personalized medicine.
    METHODS: Evidence from pharmacogenomic studies, centralized resources (for example, PharmGKB), and in silico prediction tools (such as PolyPhen and SIFT) is synthesized to illustrate how genetic variants affecting drug metabolism, efficacy, and toxicity are systematically analysed and translated into clinical applications.
    KEY FINDINGS: Pharmacogenomic applications in psychiatry, cardiology, oncology, and autoimmune disorders show that genetically guided therapies can enhance efficacy and reduce adverse effects. AI and machine learning improve interpretation of high-dimensional pharmacogenomic data, accelerating progress in precision medicine and drug discovery, although challenges such as computational complexity, data privacy, and underrepresentation of diverse populations persist.
    CONCLUSIONS: Bioinformatics technologies are central to operationalizing pharmacogenomics by enabling robust variant interpretation and data integration for individualized therapy. Addressing technical, ethical, and equity-related challenges will be critical to fully realizing the potential of pharmacogenomics and advancing precision health care.
    Keywords:  PharmGKB; PolyPhen; SIFT; bioinformatics; personalized medicine; pharmacogenomics
    DOI:  https://doi.org/10.1093/jpp/rgag001
  22. Health Sci Rep. 2026 Feb;9(2): e71691
       Background and Aims: Wound healing is a crucial aspect of clinical outcomes following surgical procedures. Various physiological, environmental, and lifestyle factors impact healing time and quality.
    Methods: This review is based on the latest experimental findings pertaining to surgical wound management and healing, based on a PubMed search of experiments from the last 5 years. Topics of interest were infection control, nutrition, radiation-induced skin injury (RSI), and closed-incisional negative pressure wound therapy (CiNPWT). The study mainly assesses wound healing by primary intention and focuses on easily implemented therapies.
    Results: 403 articles were screened regarding infection prevention with 336 excluded based on title and preview of content. 67 abstracts were further reviewed which yielded 32 articles for analysis. Overall, povidone-iodine is shown to improve the rate of wound healing and helps minimize complications such as infections or wound dehiscence while creating a sterile field due to its antimicrobial properties. It remains a standard of comparison for other anti-infectives. Nutritional factors such as veganism may impair surgical wound healing, whereas maintaining appropriate albumin levels may be protective. Employment of nutritional screenings may improve overall outcomes post-operatively, and oral probiotics improve soft tissue healing after incision, in at least one study. Pycnogenol® and Centellicum® may have applications to improve surgical site healing, since supplementation demonstrates improved perfusion and other favorable metrics. Management of RSI is a field of much exploration, with many topicals shown effective. Recently, hydrogels and even injection of stromal vascular factor show promising results. CiNPWT is found to improve overall surgical outcomes in diverse wounds, and sponge width is an important consideration.
    Conclusion: Consideration of the findings discussed, along with their potential combinations and applications, may serve to improve surgical wound healing.
    Keywords:  closed incisional negative pressure wound therapy; healing; iodine; nutrition; radiation‐induced skin injury; surgical wounds
    DOI:  https://doi.org/10.1002/hsr2.71691
  23. Crit Rev Microbiol. 2026 Feb 09. 1-15
      The human microbiome, comprising trillions of microorganisms across multiple body sites, is increasingly recognized as a key contributor to host immunity, metabolism, and neurobiology, influencing development and disease susceptibility throughout life. Rather than acting in isolation, microbial communities operate within a complex host-environment system shaped by genetics, diet, lifestyle, and medical exposures. Conceptually, the microbiome can be understood as part of a host-microbe meta-organism and, from a translational perspective, as a dynamic and potentially modifiable organ system. While short-term perturbations such as antibiotics may transiently disrupt microbial ecosystems, persistent maladaptive configurations, commonly termed dysbiosis, are associated with metabolic disease, chronic inflammation, neurodevelopmental disorders, and cancer, although causality remains context dependent. This review synthesizes the functional roles of beneficial microbes and their metabolites, the mechanistic and clinical implications of dysbiosis, and immune pathways shaped by microbial signals. We further discuss emerging therapeutic strategies, including dietary modulation, probiotics, engineered microbial consortia, postbiotics, and fecal microbiota transplantation, enabled by multi-omics technologies, organoid models, and computational frameworks. Key challenges include defining context-specific microbial health, ensuring durable engraftment, and addressing regulatory and ethical considerations. Framing the microbiome as a dynamic component of host physiology provides a foundation for microbiome-guided precision and preventive medicine.
    Keywords:  Human microbiota; dysbiosis; host immunity; human health; microbiota-based precision medicine
    DOI:  https://doi.org/10.1080/1040841X.2026.2629269
  24. Front Microbiol. 2025 ;16 1744574
       Background: Inflammatory bowel disease (IBD) is a chronic and recurrent intestinal disorder with rising global incidence, yet its complex pathogenesis remains poorly understood, underscoring the need to clarify the microbial mechanisms underlying intestinal inflammation. IBD is associated with a profound imbalance of the gut microbial ecosystem. However, the ecological and functional remodeling of the gut microbiota during IBD progression remains unclear. This study used metagenomic sequencing to investigate microbial composition, functional capacity, and ecological interactions in the gut microbiota of IBD patients compared with healthy individuals.
    Results: The IBD group exhibited significantly reduced microbial diversity and a distinct community structure compared with healthy controls. Pro-inflammatory genera such as g_Fusobacterium (p < 0.001) and g_Morganella (p < 0.001) were enriched, whereas short-chain fatty acid producing bacteria, including g_Ruminococcus (p < 0.0001) and g_Agathobacter (p < 0.0001), were markedly depleted. Functional annotation revealed decreased abundance of carbohydrate-active enzymes (GH3, GH44, GH53, and GH77; all p < 0.05) associated with polysaccharide degradation, together with enrichment of pathways related to immune activation and inflammation, such as the JAK-STAT and chemokine signaling pathways (p < 0.05). Co-occurrence network analysis further showed that IBD-associated microbes formed positively correlated clusters dominated by inflammatory taxa, whereas healthy microbiota were organized around SCFA-producing commensals.
    Conclusion: Compared with healthy individuals, the gut microbiota of IBD patients undergoes functional reprogramming characterized by loss of metabolic versatility and enrichment of inflammation-related pathways. These findings provide new insights into the ecological and metabolic mechanisms through which the gut microbiota contribute to intestinal inflammation and disease progression.
    Keywords:  dysbiosis; ecological network; gut microbiota; inflammatory bowel; metagenomics
    DOI:  https://doi.org/10.3389/fmicb.2025.1744574
  25. ACS Appl Bio Mater. 2026 Feb 11.
      Effective wound management requires dressings that not only protect against infection but also support tissue regeneration. In this work, we present a chia seed mucilage/poly(vinyl alcohol) (CSMP)-zinc oxide (ZnO) bilayer wound dressing composed of a dense CSMP-ZnO hydrofilm as the outer protective barrier and a porous CSMP-ZnO sponge as the inner absorbent layer. The CSMP-ZnO bilayer wound dressing is fabricated via oven-drying and freeze-drying techniques, enabling a clear functional division between the outer protective layer and the inner wound-contacting layer and resulting in a stable and well-integrated structure. Mechanical testing demonstrates that the bilayer design synergistically combines the strength of the hydrofilm and the flexibility of the sponge, leading to improved mechanical integrity compared with single-layer structures, while the incorporation of ZnO nanoparticles enhances antibacterial performance. Water vapor permeability and contact angle analyses indicate that the dressing maintains a moist wound environment and exhibits tunable wettability, which are favorable for wound exudate management. In vitro evaluation using normal human dermal fibroblasts confirms good biocompatibility at low ZnO concentrations, and inhibition zone assays demonstrate effective antibacterial activity against both Gram-positive and Gram-negative bacteria. Furthermore, in vivo assessment using a murine scald wound model shows that the CSMP-ZnO bilayer wound dressing accelerates wound closure and promotes re-epithelialization compared with untreated wounds. Overall, this study highlights the CSMP-ZnO bilayer wound dressing as a multifunctional platform that integrates mechanical support, moisture regulation, antibacterial protection, and biocompatibility for advanced wound care applications.
    Keywords:  Bilayer; Chia Seed Polysaccharide; Hydrogel; Wound Dressing; Zinc Oxide Nanoparticles
    DOI:  https://doi.org/10.1021/acsabm.5c02565
  26. bioRxiv. 2026 Jan 28. pii: 2026.01.28.702367. [Epub ahead of print]
      Bacteriophages ("phage") are viruses that prey on bacteria in diverse environments, from biological tissues to soils. In many of these environments, bacterial hosts are constantly migrating, yet how bacterial migration is influenced by phage predation remains poorly understood. Using transparent granular hydrogels that mimic natural habitats, we directly visualize populations of motile Escherichia coli encountering lytic T4 phage. Unexpectedly, we find that even in phage-rich environments, bacteria successfully form chemotactic fronts that enable them to migrate over large distances without needing to develop phage resistance. Higher phage concentrations delay front formation but not steady-state front speed or shape. By combining our experiments with biophysical modeling, we demonstrate that this phenomenon arises from the ability of cells to collectively outrun trailing phage bursts-as quantified by a dimensionless "escape parameter" comparing chemotactic and predation rates. This work thus reveals and provides mechanistic insight into the role of cell motility in shaping phage-bacteria interactions in spatially-extended environments.
    DOI:  https://doi.org/10.64898/2026.01.28.702367
  27. J Orthop Case Rep. 2026 Feb;16(2): 346-354
       Introduction: Negative pressure wound therapy (NPWT) has emerged as a highly effective technique for managing chronic non-healing wounds. However, the high cost and limited accessibility of commercial NPWT systems restrict their routine use in resource-constrained settings. This study aims to evaluate the efficacy of an indigenously developed simplified negative pressure wound dressing (SNPWD) for wound management in a low-resource environment.
    Materials and Methods: This prospective cohort study was conducted on 24 patients with a mean wound size pre-SNPWD being 73.5cm2 in the Department of Orthopaedics at a tertiary care hospital. Final wound area, total duration of SNPWD application, number of dressing changes, and the exudate collection, along with culture report, were documented for outcome comparison with data from existing NPWT literature.
    Results: The decrease in mean wound surface area after SNPWD application in our study was 27.2%. The mean duration of SNPWD application, that is, the time taken for development of healthy granulation tissue, ranged from 8 to 27 days, the mean duration being 16.5 days. The mean number of dressings applied per patient was 5.3. The mean amount of exudates collected in the canister decreased by 58% as compared to pre-SNPWD. The post-SNWPD culture report of wounds was sterile in 96% of cases, as compared to only 37.5% sterile culture reports before applying SNPWD.
    Conclusion: The SNPWD is a safe, effective, and cost-efficient alternative to commercial NPWT systems. With comparable clinical outcomes and significantly lower cost, SNPWD holds strong potential for widespread use in managing complex wounds, especially in resource-limited settings.
    Keywords:  Wound healing; infection; negative pressure wound dressing; vacuum-assisted closure
    DOI:  https://doi.org/10.13107/jocr.2026.v16.i02.6848
  28. Nat Microbiol. 2026 Feb 12.
      Cystitis is a bacterial infection of the bladder that occurs in about half of women at least once in their lifetime. Antibiotics such as nitrofurantoin are used to treat cystitis, but antibiotic resistance is a concern, especially for recurrent infections. Here we report an open-label, randomized, single-centre, phase 2 study to analyse the acute and long-term safety and efficacy of the IL-1 receptor antagonist anakinra, compared with nitrofurantoin, in recurrent cystitis. A total of 30 adult female patients with a documented history of recurrent cystitis and a current acute cystitis episode were randomized in a 2:1 ratio to treatment with anakinra (n = 20) or nitrofurantoin (n = 10) for 5 days. Primary and secondary efficacy end-points were reached, defined as the reduction in typical symptoms, measured by the acute cystitis symptom score (day 5), longitudinal symptom scores, recurrence rates, quality of life, gene expression analysis and microbiology at follow-up on days 15 and 30 and at 6 months. Symptom scores were decreased in the anakinra (P < 0.001) and nitrofurantoin (P < 0.001) arms after 5 days and remained low after 15 days, 30 days and 6 months. Recurrences were less frequent after 6 months in both treatment groups compared with the 6-month pre-enrolment history (P < 0.001 for anakinra and P = 0.004 for nitrofurantoin), and the quality of life was increased, without adverse effects. Immune gene expression was rapidly inhibited in the anakinra-treated patients but not in the nitrofurantoin group. Targeted innate immune inhibition therapy shows non-inferiority to nitrofurantoin in patients with recurrent acute cystitis. German Clinical Trials Register ID: DRKS00025964 .
    DOI:  https://doi.org/10.1038/s41564-026-02262-1
  29. Allergy. 2026 Feb 07.
      In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way-through the clinical use of monoclonal antibodies-a deeper understanding of how inflammatory and immune pathways are configured in disease-specific patterns. In this biomarker-driven approach, synthetic small molecule drugs (SMDs) were perceived as lagging behind in innovation for their relative lack of specificity. This was, however, mostly due to a shift in focus towards biologics rather than true obsolescence of SMDs. In the same timeframe, in fact, advances in structural biology and medicinal chemistry, bioinformatics and artificial intelligence held steadily SMDs' innovation and relevance. The use of kinase inhibitors, well established in the treatment of cancer and rheumatological diseases, is now approved for some allergic skin diseases and is approaching asthma and COPD with several clinical trials; moreover, new therapeutics targeting mast cell receptors and molecules involved in innate immunity are entering preclinical and clinical testing. Alongside, the portfolio of biologics is harboring the expansion of RNA therapeutics, which gained global recognition during the COVID-19 pandemic due to RNA vaccines. Different types of RNA therapeutics, including those based on different non-coding RNAs, are advancing to agency approval and market, thanks to improvements in molecule stability and delivery systems. In summary, the evidence presented in this position paper illustrates that precision medicine is becoming a goal shared between synthetic SMDs and biologics, both protein/antibody-based and RNA therapeutics. We review the current state, unmet needs and opportunities within this evolving landscape, highlighting how small molecular species, both synthetic as SMDs and biologic in nature as RNA, can contribute to the precision medicine approach along with protein and antibody-based biologics and cell therapies.
    Keywords:  RNA‐based therapies; biomarker‐driven drug development; chronic inflammatory diseases; kinase inhibitors; precision medicine; small molecule drugs
    DOI:  https://doi.org/10.1111/all.70235
  30. BMC Med Inform Decis Mak. 2026 Feb 07.
      
    Keywords:  Clinical decision support systems; Diabetic foot ulcer; Offloading footwear; Orthotics; Plantar pressure; Precision medicine; Ulcer healing
    DOI:  https://doi.org/10.1186/s12911-026-03349-9
  31. Virulence. 2026 Dec;17(1): 2629132
      Staphylococcus aureus (S. aureus) bloodstream infections pose a significant clinical threat, exacerbated by increasing antibiotic resistance and high mortality. While the gut microbiota is recognized as a key modulator of systemic immunity, the mechanisms underlying its protective role against invasive bacterial infections remain incompletely understood. Here, we investigated how gut microbiota influences hepatic immune responses during early S. aureus bloodstream infection using animal models. Our findings demonstrate that the gut microbiota exerts a protective effect against systemic S. aureus infection. Specifically, commensal microbiota-derived signals prime hepatic γδ T cells for rapid interleukin-17A (IL-17A) production upon bacterial challenge. This microbiota-dependent IL-17A response subsequently promotes neutrophil recruitment to the liver, facilitating bacterial clearance and limiting systemic dissemination. Disruption of the gut microbiota impaired hepatic γδ T cell IL-17A production, reduced neutrophil mobilization, and compromised host resistance to infection. Notably, we found that colonization with the commensal Limosilactobacillus reuteri (L. reuteri) activates this hepatic γδT17-neutrophil axis, enhancing host defense against S. aureus as a mechanism involving indole metabolites. This study reveals a novel gut-liver axis whereby intestinal microbiota orchestrates hepatic γδ T cell function to establish an early immunological barrier against invasive bacterial pathogens, offering potential therapeutic avenues for enhancing host defense against life-threatening S. aureus infections.
    Keywords:  IL-17A; S. aureus; gut microbiota; neutrophils; systemic infection; γδ T cells
    DOI:  https://doi.org/10.1080/21505594.2026.2629132
  32. Evolution. 2026 Feb 11. pii: qpag022. [Epub ahead of print]
      Viruses typically have high decay rates (mortality rates outside hosts), and applications of phage viruses for combating harmful bacterial in clinical and agricultural contexts would favor slow-decaying phage materials. There is evidence for a trade-off between viral survival and growth rate, which may constrain the evolution of reduced decay rate. Temperature is likely to affect the optimal balance of this trade-off; for example, faster growth may be more beneficial at warmer temperatures where phages spend less time outside of hosts in waiting for encountering a new host individual. We tested this hypothesis by experimentally evolving a lytic phage that infects the bacterium Pseudomonas fluorescens. Phages evolved at two temperatures for 20 cycles of dilution and propagation, with the ancestral bacteria being supplied every cycle. Phage populations from different temperatures showed different modes of adaptation in growth and decay traits. In particular, phages that evolved at the colder temperature showed a reduction in decay rate, regardless of assay conditions. Our results suggest phage training programs and resource collecting efforts to focus on cold environments for slow-decaying phage materials.
    Keywords:  adaptation; decay rates; experimental evolution; growth rates; life-history; virus
    DOI:  https://doi.org/10.1093/evolut/qpag022
  33. Front Med (Lausanne). 2026 ;13 1765047
      The gut microbiota is fundamental to human health, maintaining intricate symbiotic interactions with the host. Accumulating evidence highlights a critical association between gut microbiota dysbiosis and the initiation and progression of chronic liver diseases (CLDs). Particularly hepatitis B virus (HBV)/hepatitis C virus (HCV) infection, alcoholic liver disease (ALD), metabolic-associated steatotic liver disease (MASLD), and cirrhosis. This microbial imbalance may contribute to the progression of CLDs primarily via the "gut-liver axis," the mechanisms involve gut barrier dysfunction, abnormal immune regulation, and metabolic alterations. This review synthesizes cutting-edge research on the interplay between gut dysregulation and CLDs, elaborating molecular mechanistic pathways including the TLR4/NF-κB signaling pathway, AMPK pathway, and farnesoid X receptor (FXR)-mediated bile acid signaling. Additionally, it discusses clinically oriented therapeutic strategies targeting microbiota modulation, including probiotics, fecal microbiota transplantation (FMT), and personalized dietary interventions, offering innovative insights for the prevention and management of chronic liver diseases.
    Keywords:  alcoholic liver disease; chronic liver disease; cirrhosis; gut microbiota dysbiosis; gut-liver axis; mechanism; metabolic-associated steatotic liver disease; viral hepatitis
    DOI:  https://doi.org/10.3389/fmed.2026.1765047
  34. Proc Jpn Acad Ser B Phys Biol Sci. 2026 ;102(2): 82-103
      Metagenomics has become a powerful approach for deciphering the structure and function of the human gut microbiome, a complex microbial ecosystem in the gut. The human gut microbiome plays a crucial role in health and disease through multifaceted interactions with various factors, including age, diet, lifestyle, and medications. This review summarizes key advances in gut microbiome research over the past two decades and presents several topics from a recent large-scale, data-driven study, specifically a cohort-based initiative, the Japanese 4D microbiome project. These include a population-level characterization of the Japanese gut microbiome in a global context through comparison with 31,695 gut metagenomes from 37 countries, as well as an extensive analysis of the effects of medications. This review provides new insights into the ecology and uniqueness of the Japanese gut microbiome and highlights the importance of large-scale, well-phenotyped cohorts in advancing microbiome science.
    Keywords:  Japanese gut microbiome; large-scale; lifestyle; metagenomics; polypharmacy; precision medicine
    DOI:  https://doi.org/10.2183/pjab.102.006